Otosclerosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Otosclerosis}} Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. {{CMG}} ==Overview=..." |
m Bot: Removing from Primary care |
||
| (One intermediate revision by one other user not shown) | |||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Less successful treatment includes fluoride administration, which theoretically becomes incorporated into bone and inhibits otosclerotic progression. This treatment cannot reverse conductive hearing loss, but may slow the progression of both the conductive and sensorineural components of the disease process. Recently, some success has been reported with bisphosphonate medications, which stimulate bone-deposition without stimulating bony destruction. | Less successful treatment includes [[fluoride]] administration, which theoretically becomes incorporated into bone and inhibits otosclerotic progression. This treatment cannot reverse conductive hearing loss, but may slow the progression of both the conductive and sensorineural components of the disease process. Recently, some success has been reported with [[bisphosphonate]] medications, which stimulate bone-deposition without stimulating bony destruction. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WikiDoc Sources}} | |||
{{WH}} | |||
[[Category:Otolaryngology]] | [[Category:Otolaryngology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Latest revision as of 23:31, 29 July 2020
Template:Otosclerosis Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Less successful treatment includes fluoride administration, which theoretically becomes incorporated into bone and inhibits otosclerotic progression. This treatment cannot reverse conductive hearing loss, but may slow the progression of both the conductive and sensorineural components of the disease process. Recently, some success has been reported with bisphosphonate medications, which stimulate bone-deposition without stimulating bony destruction.